Form 4 Filing for AN2 Therapeutics, Inc.

This Form 4 filing details a transaction by Gilbert Lynn Marks, a director at AN2 Therapeutics, Inc. On April 10, 2026, Mr. Marks acquired 3,775 shares of Common Stock. These shares were issued in lieu of cash compensation under the company's non-employee director compensation policy and vest immediately. The transaction code is "A", indicating an acquisition. Following this transaction, Mr. Marks now owns 79,084 shares of Common Stock, with ownership being direct.